Pancreatic cancer
Conditions
Interventions
Experimental group:Confirming pancreaticoduodenectomy through improved MDT diagnosis and treatment mode
Control group:Direct pancreaticoduodenectomy in pancreatic surgery
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1). Patients who attended the Department of Pancreatic Surgery at West China Hospital of Sichuan University from July 2023 to June 2024; 2). Elderly patients over 70 years old; 3) Proposed pancreaticoduodenectomy; 4). Sign written informed consent;
Exclusion criteria
Exclusion criteria: 1). The presence of non-locally progressive tumors with definite extraperitoneal metastasis (M1); 2) Simultaneously have serious or uncontrolled medical disease and infected persons; 3). Patients whose seizures require treatment (e.g. steroid or anti-epileptic therapy); 4). Any unstable condition or situation that may compromise the patient's safety and compliance;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival;Incidence of adverse reactions;Complication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Surgical duration and bleeding volume;Hospitalization days;Hospitalization expenses;90 day readmission rate;numerical rating scale,NRS; | — |
Countries
China
Contacts
Public ContactBole Tian
Department of Pancreatic Surgery, West China Hospital, Sichuan University
Outcome results
None listed